Dr Clifford Rossi (University of Maryland)

article

Economics and risks of FDA’s Quality management maturity rating programme

29 September 2022 | By Dr Clifford Rossi (University of Maryland)

Ensuring that pharmaceutical manufacturers not only adhere to current good manufacturing processes but go beyond to embrace a culture of quality has far-reaching consequences for the industry, the health care community and consumers. A focus on quality across many sectors of the economy has demonstrated direct economic benefits accruing to…

article

Can continuous manufacturing add shareholder value for pharmaceutical companies?

28 April 2022 | By Dr Clifford Rossi (University of Maryland)

A recent empirical study of continuous manufacturing (CM) versus batch processing of US and non‑US pharmaceutical manufacturing facilities suggests that CM would be more economical than batch facilities, at least for the production of oral solid dosage products. This has significant consequences for policies and strategies to reduce supply chain…